<DOC>
	<DOCNO>NCT02081443</DOCNO>
	<brief_summary>Cangrelor potent intravenous P2Y12 receptor inhibitor rapid onset offset action associate great reduction ischemic event , include stent thrombosis , patient undergoing stent procedure pretreated clopidogrel . In vitro investigation show cangrelor associate rapid , potent , consistent platelet inhibition patient maintenance prasugrel therapy expose re-loading dose prasugrel . However , cangrelor exerts similar effect ticagrelor treat patient remain unknown . The aim present study evaluate effect platelet function achieve vitro incubation cangrelor patient ticagrelor maintenance dose receive loading dose ticagrelor .</brief_summary>
	<brief_title>In Vitro Pharmacodynamic Effects Cangrelor Ticagrelor Treated Patients</brief_title>
	<detailed_description>A high degree platelet inhibition remain goal peri-interventional period patient undergo percutaneous coronary intervention ( PCI ) associate low rate adverse ischemic event . Ticagrelor prasugrel novel potent generation oral P2Y12 receptor inhibitor associate great reduction ischemic event compare clopidogrel . However , prasugrel ticagrelor recently show variability pharmacodynamic ( PD ) response , particularly patient ST-elevation myocardial infarction ( STEMI ) undergo primary PCI , expose patient increase risk thrombotic complication . These finding support need intravenous agent rapid platelet inhibit effect . Cangrelor potent intravenous P2Y12 receptor inhibitor rapid onset offset action associate great reduction ischemic event , include stent thrombosis , patient undergo PCI pretreated clopidogrel . In vitro PD investigation show cangrelor associate rapid , potent , consistent platelet inhibition patient maintenance prasugrel therapy expose re-loading dose prasugrel . However , cangrelor exerts similar effect ticagrelor treat patient remain unknown . The aim present study evaluate PD effect achieve vitro incubation cangrelor patient ticagrelor maintenance dose receive loading dose ticagrelor . The propose study prospective , randomize , parallel design patient chronic ticagrelor therapy assign receive reloading dose 90 180 mg ticagrelor . PD assessments do incubation cangrelor 3 time-points . The study hypothesis vitro incubation cangrelor lead incremental P2Y12 receptor blockade , extent inversely relate dose ticagrelor .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients angiographically document coronary artery disease . 2 . Age 18 80 year 3 . On treatment per standard care ticagrelor 90mg/b.i.d . aspirin &lt; 100mg/day least 14 day . Exclusion criteria 1 . History intracranial bleeding 2 . Known severe hepatic dysfunction 3 . Known hypersensitivy 4 . Active bleeding propensity bleed 5 . Platelet count &lt; 80x106/mL 6 . Hemodynamic instability 7 . Serum creatinine &lt; 30 mL/min 8 . Use oral anticoagulant ( Vitamin K antagonist , dabigatran , rivaroxaban , apixaban ) 9 . Recent ( &lt; 14 day ) antiplatelet treatment glycoprotein IIb/IIIa inhibitor 10 . Blood dyscrasia 11 . Patients sick sinus syndrome ( SSS ) II III degree AV block without pacemaker 12 . Drugs interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromicin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir telithromizycin 13 . Hemoglobin &lt; 10g/dL 14 . Pregnant female [ woman childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>platelet function</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>cangrelor</keyword>
</DOC>